| Theme |
An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease |
| Title |
Biologics and small molecule drugs currently under development for inflammatory bowel disease |
| Author |
Minoru Matsuura |
Department of Gastroenterology and Hepatology, Kyorin University School of Medicine |
| Author |
Tadakazu Hisamatsu |
Department of Gastroenterology and Hepatology, Kyorin University School of Medicine |
| [ Summary ] |
Since the advent of TNF-α antagonists, along with the elucidation of the pathophysiology of inflammatory bowel disease (IBD), there has been rapid progress in the development of novel therapeutic agents targeting specific molecules that play a key role in the pathogenesis of IBD. Currently, the development of IBD therapeutics is focused on drugs that inhibit specific cytokines and their intracellular signaling, and drugs that regulate the dynamics of lymphocytes in lymphoid tissues and the gastrointestinal tract. In addition to evaluating the efficacy and safety of these novel therapeutic agents under development, it is necessary to determine their role in the treatment of IBD. The development of molecular targeted drugs with mechanisms of action different to those of conventional IBD drugs is expected to contribute to further improvements in the quality of life of patients with IBD. |